此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项评估IDCT(椎间盘内细胞疗法)在单节段、有症状的轻中度腰椎退行性椎间盘疾病受试者中有效性的研究 (IDCT)

2026年10月14日 更新者:DiscGenics, Inc.

一项前瞻性、随机、双盲、假对照、多中心研究,旨在评估IDCT对单节段、症状性轻度至中度腰椎间盘退行性变患者的安全性和有效性

This is a Phase III, randomized, double-blinded, Sham-controlled, multi-center study in subjects with single-level, symptomatic lumbar (L3- S1) intervertebral disc degeneration. The study will have a 52-week primary period followed by 52 week Follow-up Period (total of 104 weeks).

The study protocol will be approved by the Institutional Review Board (IRB) or Independent Ethics Committee (IEC), and the study will be conducted in accordance with Good Clinical Practice (GCP). All subjects will provide written informed consent prior to Screening.

Approximately 162 subjects will be enrolled in the study. Up to 45 days prior to treatment, subjects will be screened for study inclusion, which includes obtaining baseline MRI and X-ray imaging. Imaging results for subjects initially eligible for study participation will be sent to a central imaging vendor for review and confirmation of eligibility, including the number of levels with degeneration. Subjects meeting all inclusion/exclusion criteria will be assigned to the corresponding treatment arm group and subsequently randomized to IDCT or Sham.

Randomization will occur approximately 7 to 14 days prior to the scheduled treatment administration date.

Overall, 162 subjects will be enrolled and randomized to IDCT or Sham in a 2:1 ratio.

  • IDCT (n=108)
  • Sham (n=54)

研究概览

详细说明

Adult subjects with a diagnosis of single-level, mild to moderate, symptomatic lumbar (L3-S1) intervertebral disc degeneration that give consent and meet all the inclusion criteria and none of the exclusion criteria will be enrolled in this study. The disease, single-level disc will be known as the 'target disc' and will be either L3/L4, L4/L5, or L5/S1.

研究类型

介入性

注册 (估计的)

162

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Alabama
      • Birmingham、Alabama、美国、35235
        • 招聘中
        • Alabama Clinical Therapeutics
        • 首席研究员:
          • Brad 205-833-2228, MD
        • 接触:
    • Arizona
      • Phoenix、Arizona、美国、85054
        • 招聘中
        • Mayo Clinic (AZ)
        • 首席研究员:
          • John Freeman, MD
        • 接触:
      • Scottsdale、Arizona、美国、85251
        • 招聘中
        • HonorHealth
        • 首席研究员:
          • Luis Tumialan, MD
        • 接触:
    • Arkansas
      • Little Rock、Arkansas、美国、72205
        • 招聘中
        • University of Arkansas for Medical Sciences
        • 接触:
        • 首席研究员:
          • Erica Petersen, MD
    • California
      • San Diego、California、美国、92111
        • 招聘中
        • Solaris Research Institute
        • 首席研究员:
          • Krishnan Chakravarthy, MD
        • 接触:
      • Santa Monica、California、美国、90403
        • 招聘中
        • Source Healthcare
        • 首席研究员:
          • Timothy Davis, MD
        • 接触:
      • Thousand Oaks、California、美国、91320
        • 招聘中
        • Pain Management and Injury Relief
        • 接触:
        • 首席研究员:
          • Alexander Hersel, MD
    • District of Columbia
      • Washington D.C.、District of Columbia、美国、20006
        • 招聘中
        • International Spine, Pain and Performance Center
        • 首席研究员:
          • Mehul Desai, MD
        • 接触:
    • Florida
      • Jacksonville、Florida、美国、32224
        • 招聘中
        • Mayo Clinic (FL)
        • 接触:
        • 首席研究员:
          • Wenchun Qu, MD
      • Miami、Florida、美国、33136
        • 招聘中
        • University of Miami Health System
        • 接触:
        • 首席研究员:
          • Barth Green, MD
      • Orlando、Florida、美国、32832
      • St. Petersburg、Florida、美国、33709
        • 招聘中
        • Vantage Clinical Trials
        • 首席研究员:
          • Robert Guirguis, MD
        • 接触:
      • Tampa、Florida、美国、33709
        • 招聘中
        • Vantage Clinical Trials
        • 首席研究员:
          • Jorge Leal, MD
        • 接触:
    • Idaho
      • Boise、Idaho、美国、83709
        • 终止
        • Injury Care Family Care Research
      • Post Falls、Idaho、美国、83854
    • Illinois
      • Chicago、Illinois、美国、60612
        • 招聘中
        • Rush University Medical Center
        • 首席研究员:
          • John O'Toole, MD
        • 接触:
    • Indiana
      • Carmel、Indiana、美国、46032
        • 招聘中
        • Indiana Spine Group
        • 接触:
        • 首席研究员:
          • Kevin Macadaeg, MD
    • Kentucky
      • Louisville、Kentucky、美国、40202
        • 招聘中
        • Norton Leatherman Spine Center
        • 接触:
        • 首席研究员:
          • Steven Glassman, MD
    • Louisiana
      • New Orleans、Louisiana、美国、70121
        • 招聘中
        • Ochsner Health System
        • 首席研究员:
          • Maged Guirguis, MD
        • 接触:
    • Minnesota
      • Rochester、Minnesota、美国、55905
        • 招聘中
        • Mayo Clinic (MN)
        • 首席研究员:
          • Ryan D'Souza, MD
        • 接触:
    • Missouri
      • St Louis、Missouri、美国、63141
        • 招聘中
        • The Orthopedic Center of St. Louis
        • 接触:
        • 首席研究员:
          • Matthew Gornet, MD
    • New York
      • New York、New York、美国、10022
        • 招聘中
        • Weill Cornell Medicine for Comprehensive Spine Care
        • 接触:
        • 首席研究员:
          • Prabhav Deo, MD
    • North Carolina
      • Wilmington、North Carolina、美国、28403
        • 招聘中
        • Wake Research
        • 首席研究员:
          • Jeremy Hoff, MD
        • 接触:
      • Winston-Salem、North Carolina、美国、27103
        • 招聘中
        • Carolinas Pain Institute/ Center For Clinical Research
        • 首席研究员:
          • Christopher Gilmore, MD
        • 接触:
    • Ohio
      • Cleveland、Ohio、美国、10524
        • 招聘中
        • Cleveland Clinic
        • 接触:
        • 首席研究员:
          • Jijun Xu, MD
    • Oregon
      • Eugene、Oregon、美国、97404
        • 招聘中
        • Pacific Sports and Spine
        • 首席研究员:
          • Gregory Moore, MD
        • 接触:
    • Pennsylvania
      • King of Prussia、Pennsylvania、美国、19406
        • 招聘中
        • Main Line Spine
        • 首席研究员:
          • Scott Davidoff, MD
        • 接触:
    • Tennessee
      • Memphis、Tennessee、美国、38120
    • Texas
      • Austin、Texas、美国、78745
        • 招聘中
        • Pain Specialists of America
        • 首席研究员:
          • Genaro Gutierrez, MD
        • 接触:
    • Utah
      • Salt Lake City、Utah、美国、84108
        • 招聘中
        • University of Utah
        • 首席研究员:
          • Zachary McCormick, MD
        • 接触:
    • Virginia
      • Richmond、Virginia、美国、23238
        • 招聘中
        • Virginia iSpine Physicians
        • 首席研究员:
          • Michael DePalma, MD
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 75年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Has a diagnosis of mild to moderate, symptomatic, single-level degenerative disc disease (DDD) from L3-S1.

  2. Has a target disc that meets Modified Pfirrmann Grade 3-7, as determined by a central radiologist.

  3. Is ≥18 and ≤75 years of age, skeletally mature, and has a body mass index (BMI) ≥18 kg/m2 and ≤38 kg/m2 at Screening.

  4. Has been experiencing chronic low back pain for at least 6 months prior to Screening.

  5. Has had low back pain that is unresponsive to at least 3 months of conservative care (nonoperative treatment) to include at least one non-pharmacological intervention which may include physical therapy, acupuncture, chiropractic manipulation, massage, and at home medically supervised exercise program and two pharmacological interventions which may include NSAIDs, acetaminophen, duloxetine, and/or injectable therapy.

  6. Has pre-treatment low back pain score of 45 to 90 on VAS (Visual Analogue Scale) for low back pain at Screening and Day 1.

  7. Has pre-treatment ODI score of 35 to 90 at Screening and Day 1.

  8. Is willing to voluntarily sign the informed consent form and agrees to the release of previous medical history for purposes of this study (i.e., HIPAA authorization) at Screening.

  9. Is physically and mentally able to comply with the protocol, able to understand and complete the required forms, and willing and able to adhere to the requirements of the protocol in the opinion of the Investigator.

  10. Female-born subjects of childbearing potential must agree to and comply with using highly effective methods of birth control for the duration of the study (e.g., oral contraceptive, implant, injectable, indwelling intrauterine device, sexual abstinence, condoms, or a vasectomized partner).-

    Exclusion Criteria:

    Physical/ Medical History Exclusion Criteria

  11. Has low back pain that in the Investigator's opinion is predominately myofascial in nature.

  12. Has constant, unchanging low back pain that is not improved in any spinal position.

  13. Has radiculopathy resulting from nerve compression.

  14. Has non-radicular unilateral or bilateral leg pain with intensity greater than 50% of the intensity of the low-back pain, as measured by VAS.

  15. Leg pain that is of radicular origin, i.e., due to stimulation of nerve roots or dorsal root ganglion of a spinal nerve by compressive forces.

  16. Has frequent leg pain that extends below the knee.

  17. Has severe unilateral or bilateral osteoarthritis of the knee or hip.

  18. Severe spinal arthritis

  19. Has cauda equina syndrome.

  20. Has had previous lumbar spine surgery.

  21. Has had previous disc invasive treatment procedures (i.e., intradiscal electrothermal therapy, intradiscal radiofrequency thermocoagulation) or intradiscal injections (i.e., injection of corticosteroids, methylene blue, dextrose, or glucosamine and chondroitin sulfate) or diagnostic discography at L3-S1 within the 3 months prior to Screening.

  22. Subjects who have had basivertebral nerve ablation at L3-S1.

  23. Has clinical suspicion of facet pain as the primary pain generator.

  24. Has current infection at the planned procedure site, active systemic infection, or current or prior history of lumbar spinal infection (i.e., discitis, septic arthritis, epidural abscess).

  25. Has a history of fibromyalgia.

  26. Has tested positive for Hepatitis B virus (HBV), Hepatitis C virus (HCV), or Human Immunodeficiency Virus (HIV).

  27. Has presence of an active malignancy or tumor, or a prior history of malignancy within the last five years (except for basal cell carcinoma of the skin).

  28. Has presence or prior history of a spinal malignancy.

  29. Has significant systemic disease, such as unstable angina or autoimmune disease, such as rheumatoid arthritis. Has a history of congenital or acquired coagulopathy or thrombocytopenia.

31. Is currently taking anticoagulant, antiplatelet, or thrombolytic medications (except for aspirin or nonsteroidal anti-inflammatory drugs [NSAIDS]) and at the Investigator's medical discernment and discretion is unable to withhold medications for the time required per site standard or care, prior to the IDCT injection or is taking antineoplastic medications.

32. Is at higher risk for post-surgical infection (e.g., taking immunosuppressants), has a severe infection or a history of serious infection.

33. Has concomitant conditions requiring daily oral steroid usage for more than 30 days in the preceding 90 days before Screening.

34. Is taking opioids greater than 20 MME per day on an intermittent (as needed) basis OR is taking 20 MME or greater daily for more than 3 months prior to Screening

35. Has a history of unexplained, easy, or persistent bruising or bleeding, bleeding from the gums, or bleeding problems experienced in previous surgical procedures.

36. Has a history of hypersensitivity or anaphylactic reaction to bovine products, sodium hyaluronate/ hyaluronan/ hyaluronic acid, gentamicin, amphotericin b, dimethyl sulfoxide (DMSO), crustaceous/ shellfish, or porcine products.

37. Has an uncontrolled psychiatric condition or substance/alcohol abuse that would potentially interfere with the subject's participation in the study within 2 years prior to Screening in the opinion of the Investigator.

38. Has positive serum pregnancy test or nursing at time of Screening or has plans to become pregnant within the planned length of the study (2 years).

39. Has a body habitus that precludes adequate fluoroscopic visualization for the procedure or the procedure is physically impossible.

40. Has or requires an implantable electronic defibrillator, pacemaker, or has other contraindication to MRI scanning or cannot tolerate MRI scanning. Subjects who are expected to require a defibrillator or pacemaker, as determined by the Investigator should be excluded.

41. Has participated in another clinical study within the 6 months prior to Screening.

42. Has been a recipient or plans to be a recipient during trial participation of stem cell product to treat the lumbar spine.

43. Has participated in a prior IDCT clinical study.

44. Has pending litigation against a health care professional, except where required by the insurer as a condition of coverage.

45. A person who would not be available for the entire planned length of the trial.

46. Has active or pending worker's compensation claims. 47. In the Investigators opinion, the subject is not suitable for participation in the clinical trial.

Imaging Exclusion Criteria:

48. Three discs (L3-S1) that have a Modified Pfirrmann Grade 4-7.

49. Has evidence of prior lumbar vertebral body fracture at L3-S1.

50. Has scoliosis with curvature > 10 degrees.

51. Has congenital spinal irregularities such as segmentation.

52. Has an acute fracture of the spine at the time of enrollment in the study. Clinically compromised vertebral bodies within L3-S1 due to current or past trauma, e.g., sustained pathological fracture or multiple fractures of vertebrae.

53. Has evidence of dynamic instability on lumbar flexion extension per screening radiographs as indicated by >4.5 mm of translational motion at L3-S1; >15° of angular motion at L3/-L4; >20° of angular motion at L4-L/5; or >25° angular motion at L5/-S1.

54. Has Grade 2 or higher spondylolisthesis at L3-S1, as assessed by Meyerding classification.

55. Has lumbar spondylitis or other undifferentiated spondyloarthropathy.

56. Has Modic Type III Changes at L3-S1.

57. Has radiographic evidence or suspicion of a full thickness annular tear at L3-S1.

58. Has evidence of abnormal disc morphology defined as an extrusion or sequestration according to Fardon classification at L3- S1.

59. Has herniation > 3 mm in AP dimension that is associated with nerve root compression.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:IDCT (n=108); Intradiscal injection of IDCT in a single target disc

1 mL intradiscal injection of 9,000,000 cells/mL

Single intradiscal injection of 1 mL of 9,000,000 cells/mL IDCT in a single target disc.

假比较器:Sham (n=54);

Needle insertion up to the annulus of a single target disc.

Single Sham needle insertion up to the annulus of a single target disc.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Visual Analogue Scale (VAS) for low back pain
大体时间:Week 52

VAS is a sliding visual scale of 0 being "no pain" and 100 being "worst pain Imaginable' to assess changesfrom baseline in low back pain compared to Sham

Week 52
Oswestry Disability Index (ODI)
大体时间:Week 52

ODI is a 10-item questionnaire used to measure functional disability in people with low back pain. It is a self-administered tool that assesses how back pain affects daily activities like walking, sleeping, and personal hygiene, with scores ranging from 0% (no disability) to 100% (maximum disability).

Week 52
Adverse Events
大体时间:Day 1 to Week 52 in each treatment group.

Incidence of grade 2 (moderate) or greater AEs and SAEs

Day 1 to Week 52 in each treatment group.
Adverse events of special interest
大体时间:Day 1 to Week 52 in each treatment group

Incidence of Adverse Events of Special Interest (AESI) to include any symptomatic injury of the target disc including annular tear, disc herniation/extrusion/prolapse as well as discitis.

Day 1 to Week 52 in each treatment group

次要结果测量

结果测量
措施说明
大体时间
Visual Analogue Scale (VAS)
大体时间:Week 4, 12 and 26, 78 and 104

VAS is a sliding visual scale of 0 being "no pain" and 100 being "worst pain Imaginable' to assess changes from baseline in low back pain

Week 4, 12 and 26, 78 and 104
Oswestry Disability Index (ODI)
大体时间:Week 4, 12 and 26, 78 and 105

ODI is a 10-item questionnaire used to measure functional disability in people with low back pain. It is a self-administered tool that assesses how back pain affects daily activities like walking, sleeping, and personal hygiene, with scores ranging from 0% (no disability) to 100% (maximum disability).

Week 4, 12 and 26, 78 and 105
EQ-5D
大体时间:Enrollment through Week 104

EQ-5D is a validated too consisting of a set of questions covering five dimensions, with each dimension having a different severity level.

  1. Mobility: Ranging from "no problems walking about" to "confined to bed". Self-care: Ranging from "no problems with self-care" to "unable to wash or dress myself".
  2. Usual activities: Ranging from "no problems doing my usual activities" to "unable to do my usual activities" (e.g., work, study, housework).
  3. Pain/discomfort: Ranging from "no pain or discomfort" to "extreme pain or discomfort".
  4. Anxiety/depression: Ranging from "not anxious or depressed" to "extremely anxious or depressed".
  5. Visual Analog Scale (EQ VAS): A scale (typically 0-100) where respondents mark their overall health from "worst imaginable" to "best imaginable".
Enrollment through Week 104
Disc Volume
大体时间:Day 1 to Week 104

MRI assessment of Disc Volume though Week 104

Day 1 to Week 104
Pain Medication Use
大体时间:Enrollment to Week 104

Concomitant pain medication use for low back pain related to the target disc

Enrollment to Week 104
Concomitant Therapy
大体时间:Enrollment to Week 104

Concomitant medical therapy for low back pain (physical therapy, acupuncture, chiropractic manipulation, massage, and at-home, medically supervised exercise program etc.) use for low back pain

Enrollment to Week 104
Treatment Failure Rate
大体时间:Enrollment to week 104

Treatment failure rate (defined as an invasive non-surgical or surgical intervention) directly related to the target disc.

Enrollment to week 104
Adverse Events
大体时间:Enrollment to Week 104

The incidence of grade 2 (moderate) or greater AEs and SAEs

Enrollment to Week 104
Adverse Events of Special Interest (AESI)
大体时间:Enrollment to Week 104

The incidence of Adverse Events of Special Interest (AESI) observed defined as any one of the followings symptomatic injury of the target disc including annular tear, disc, herniation/extrusion/prolapse or any case of discitis.

Enrollment to Week 104

其他结果措施

结果测量
措施说明
大体时间
MRI Based evaluations
大体时间:Enrollment through Week 104

MRI Evaluation of the lumbar spine will be reported as an aggregate in one report to assess of disc height, Modified Pfirrmann grade, Modic changes, annular tears/fissures, endplate integrity, herniation, and any additional noteworthy observations at 12, 26, 52, 78, and 104.

Enrollment through Week 104
X-ray evaluation of the lumbar spine
大体时间:Screening through Week 104

X-ray evaluation of flexion/extension will be assessed and measure in degrees of angles.

Screening through Week 104

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Lisa Flood、DiscGenics, Inc.

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年12月23日

初级完成 (估计的)

2027年11月24日

研究完成 (估计的)

2028年11月24日

研究注册日期

首次提交

2025年11月17日

首先提交符合 QC 标准的

2025年11月20日

首次发布 (实际的)

2025年11月28日

研究记录更新

最后更新发布 (实际的)

2026年10月15日

上次提交的符合 QC 标准的更新

2026年10月14日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅